ClinicalTrials.gg
CompletedNCT04172246Updated Nov 21, 2025

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

A Phase 1/2 interventional study of Zanubrutinib in Mature B-cell Malignancies, sponsored by BeiGene. Completed at 15 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by BeiGene · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 17 under way, 3 of them phase 3. zanubrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
14th of 22
55 · median 71
Started
2020
with 1 other
Phase 1/2
Only one
of the 22
Registered
6th of 22
by date
Lead sponsor
5 of 22
BeiGene

Among the 22 studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 14th largest by enrollment, is one of 2 that started in 2020, is the only one in phase 1/2, and was the 6th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

11 of the 22 studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About zanubrutinib

zanubrutinib: first FDA approval 2019 (BRUKINSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This is a Phase 1/2 study of zanubrutinib in Japanese participants with mature B-cell malignancies.

This study intends to assess the use of zanubrutinib as an investigational agent to develop new treatment options for Japanese participants with B-cell malignancies. No formal hypothesis testing will be performed given the small sample size.

03

Conditions studied

  • Mature B-cell Malignancies

Keywords

  • relapsed/refractory chronic lymphocytic leukemia
  • relapsed/refractory small lymphocytic lymphoma
  • treatment-naïve chronic lymphocytic leukemia
  • treatment-naïve /small lymphocytic lymphoma
  • relapsed/refractory mantle cell lymphoma
  • relapsed/refractory marginal zone lymphoma
  • relapsed/refractory follicular lymphoma
  • relapsed/refractory Waldenström macroglobulinemia
  • treatment-naïve Waldenström macroglobulinemia
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants with Confirmed diagnosis of mature B-cell neoplasms including chronic lymphocytic leukemia/ small lymphocytic lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma and Waldenström's macroglobulinemia
  • disease defined as disease that relapsed after, or been refractory to, at least 1 prior therapy
  • Meeting at least one of criteria for requiring treatment
  • by computed tomography (CT)/ magnetic resonance imaging (MRI) for mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and follicular lymphoma (FL) participants and by serum immunoglobulin (Ig) M level > 0.5 g/dL for WM participants
  • performance status of 0, 1, or 2
  • of > 4 months

Key Exclusion Criteria:

  • Known central nervous system involvement by lymphoma/leukemia
  • Known plasma cell neoplasm, prolymphocytic leukemia, history of or currently suspected Richter's syndrome
  • Prior stem cell transplant
  • Systemic chemotherapy or radiation therapy within 2 weeks prior to first dose of zanubrutinib
  • Active fungal, bacterial, and/or viral infection requiring systemic therapy
  • Prior therapy with B-cell receptor inhibitor (eg, Bruton tyrosine kinase, phosphoinositide 3 kinase delta, and/or spleen tyrosine kinase inhibitor) or B-cell lymphoma 2 inhibitor (eg, venetoclax/ABT-199)
  • Pregnant, lactating, or nursing women
  • anemia and/or thrombocytopenia that is poorly responsive to or other standard therapy

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Zanubrutinib

    Drug: Zanubrutinib

Interventions

  • Zanubrutinib at 160 mg orally twice daily

    Also known as: BGB-3111

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever is earlier

  2. Part 1: Number of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs)

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever is earlier

  3. Part 1: Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation of Treatment

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever is earlier

  4. Part 1: Maximum Plasma Concentration (Cmax) of zanubrutinib

    Time frame: Up to 29 days

  5. Part 1: Area under plasma concentration-time curve Concentration (AUC) of zanubrutinib

    Time frame: Up to 29 days

  6. Part 2: Overall response rate as assessed by Independent Review Committee (IRC)

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever occurs first

Secondary outcomes

  1. Part 1: Bruton tyrosine kinase (BTK) occupancy in peripheral blood mononuclear cells

    Time frame: Predose up to 24 hours postdose

  2. Part 1: Overall response rate (ORR) as assessed by the investigator

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever is earlier

  3. Part 1: Progression-free survival (PFS) as assessed by the investigator

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever is earlier

  4. Part 1: Duration of response as assessed by the investigator

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever is earlier

  5. Part 1: Time to response as assessed by the investigator

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever is earlier

  6. Part 2: Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever is earlier

  7. Part 2: Number of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs)

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever is earlier

  8. Part 2: Maximum Plasma Concentration (Cmax) of zanubrutinib

    Time frame: Predose up to 24 hours postdose Cycle 1 day 1 (C1D1) and Cycle 2 day 1 (C2D1)

  9. Part 2: Number of Participants Experiencing AEs Leading to Discontinuation of Treatment

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever is earlier

  10. Part 2: Rate of complete response for chronic lymphocytic leukemia (CLL) as assessed by IRC

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever is earlier

  11. Part 2: Rate of complete response with incomplete marrow for CLL as assessed by IRC

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever is earlier

  12. Part 2: Rate of complete response for small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), and Waldenström macroglobulinemia (WM) as assessed by IRC

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever is earlier

  13. Part 2: Rate of very good partial response (VGPR) or better for WM as assessed by IRC

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever is earlier

  14. Part 2: Major response rate (partial response or better) for WM as assessed by IRC

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever is earlier

  15. Part 2: Rate of partial response or better for CLL as assessed by IRC

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever is earlier

  16. Part 2: Overall response rate (ORR) by disease type as assessed by the investigator

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever is earlier

  17. Part 2: Progression-free survival (PFS) as assessed by IRC

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever is earlier

  18. Part 2: Duration of response as assessed by IRC

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever is earlier

  19. Part 2: Time to response as assessed by IRC

    Time frame: Until approximately 6 months after the last dose of zanubrutinib for the last participant who discontinues zanubrutinib or zanubrutinib becomes commercially available for the participant's disease, whichever is earlier

  20. To assess the efficacy of zanubrutinib as measured by overall survival

    Time frame: Overall survival defined as time from start of study treatment to death due to any cause

07

Study locations

15 sites
  • Nagoya University Hospital
    Nagoya, Aichi-ken 466-8560, Japan
  • Toyohashi Municipal Hospital
    Toyohashishi, Aichi-ken 441-8570, Japan
  • Chiba Cancer Center
    Chiba, Chiba 260-8717, Japan
  • Matsuyama Red Cross Hospital
    Matsuyama, Ehime 790 8524, Japan
  • Kurume University Hospital
    KurumeShi, Fukuoka 830-0011, Japan
  • National Hospital Organization Hokkaido Cancer Center
    Sapporo, Hokkaido 003-0804, Japan
  • Aiiku Hospital
    Sapporo, Hokkaido 064-0804, Japan
  • Kobe City Medical Center General Hospital
    KobeShi, Hyōgo 650-0047, Japan
  • Kanagawa Cancer Center
    Yokohama, Kanagawa 241-8515, Japan
  • National Cancer Center Hospital
    ChuoKu, Tokyo 104-0045, Japan
  • Aomori Prefectural Central Hospital
    Aomori, 030-8553, Japan
  • Gifu Municipal Hospital
    Gifu, 500-8513, Japan
  • The Japanese Red Cross Nagasaki Genbaku Hospital
    Nagasaki, 852-8511, Japan
  • National Hospital Organization Okayama Medical Center
    Okayama, 701-1192, Japan
  • Yokohama Municipal Citizens Hospital
    Yokohama, 221-0855, Japan
08

References and documents

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beigene.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in May 2023, 39 months.

Of 50 industry-sponsored phase 1/2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 104. This study's 39 months is below that.

Counting every sponsor, half of 90 studies reached it within 78 months; a quarter within 51 and three quarters within 103.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2019
First posted
Nov 21, 2019
StartActual
Jan 29, 2020
Primary completionActual
May 10, 2023
CompletionActual
Jun 30, 2025
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04172246
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Nov 21, 2019
Start date
Jan 29, 2020
Primary completion
May 10, 2023
Completion
Jun 30, 2025
Last update
Nov 21, 2025

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion